PROCEPT BioRobotics (PRCT) vs UFP Technologies (UFPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UFP Technologies (UFPT) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 32.2% versus a loss of 17.3%. Over five years, UFPT leads with a +319.6% price change compared with -30.6% for PRCT. UFP Technologies is the larger company by market cap ($2.25 billion vs $1.42 billion), about 1.6 times the size, while PROCEPT BioRobotics is growing revenue faster (+37.2% vs +19.5%).
UFP Technologies converts more of its revenue into profit, with a net margin of 11.3% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRCT | UFPT |
|---|---|---|
| Share price | $24.70 | $290.85 |
| Market cap | $1.42B | $2.25B |
| 1-day change | -4.08% | -2.70% |
| YTD return | -21.49% | +31.00% |
| 1-year return | -17.28% | +32.22% |
| 5-year return | -30.64% | +319.58% |
| P/E ratio (TTM) | — | 29.71 |
| Forward P/E | — | 24.09 |
| EPS (TTM) | $-2.02 | $9.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $308.05M | $602.80M |
| Revenue growth (YoY) | +37.22% | +19.50% |
| Net income (latest FY) | $-95.57M | $68.31M |
| Gross margin | 63.70% | 28.27% |
| Operating margin | -33.71% | 15.32% |
| Net margin | -31.02% | 11.33% |
| 52-week high | $38.11 | $342.11 |
| 52-week low | $16.67 | $173.86 |
| Distance from 52-week high | -35.19% | -14.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -7.89% | +22.92% |
| Average volume | 1.31M | 110.43K |
| Shares outstanding | 57.54M | 7.75M |
| Employees | 888 | 4,846 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UFPT has outperformed PRCT by 49.5 percentage points over the past year.
- UFP Technologies is more profitable, keeping 11.3 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +19.50%).
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
About UFP Technologies
UFPT stock →UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing.
Health Care · Medical/Dental Instruments · 4,846 employees
PRCT vs UFPT FAQ
Which is bigger, PROCEPT BioRobotics or UFP Technologies?
UFP Technologies (UFPT) is larger, with a market capitalization of $2.25B compared with $1.42B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, PRCT or UFPT?
UFPT returned +32.22% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are PROCEPT BioRobotics and UFP Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.